Thoracic oncology & lung cancer represent one of the most intensively researched areas in respiratory medicine, driven by high mortality rates and complex diagnostic challenges. Advances in molecular profiling and immunotherapy have enabled oncologists and pulmonologists to personalize treatment strategies based on tumor genotypes. The use of targeted therapies and checkpoint inhibitors has significantly improved survival outcomes, particularly in advanced non-small cell lung cancer. Emerging tools such as liquid biopsies and next-generation sequencing are facilitating earlier detection and better monitoring of disease recurrence. Multidisciplinary tumor boards now play a crucial role in managing comorbidities and ensuring evidence-based treatment decisions. Additionally, growing emphasis is being placed on addressing global disparities in care access, highlighting the need for international collaboration to standardize lung cancer screening and enhance equity in therapeutic advancements.